Store
Cell and Gene Therapy Deals, 2022
Publication Date: February 17, 2022
Tags: CAR-T Cell Therapy, Cell and Gene Therapy, Funding and Investments, Life Science, Mergers and Acquisitions (M&A), Oncology and Cancer
Pages: 155
SKU: 22-054
The cell and gene therapy (CGT) sector has experienced remarkable growth, with funding reaching $70 billion in 2021. As barriers to entry lower and the number of approved therapies with proven track records increases, over a thousand companies have entered or expanded within this dynamic field. Keeping up with this rapidly evolving industry is essential, and Kalorama Information’s latest report, Cell and Gene Therapy Deals: Financings, Partnering, M&A, Technology Transfers, IPOs, and Other Developments, 2022, provides comprehensive insights into the myriad deals shaping the CGT landscape.
Key Highlights:
- Funding and Investments: Detailed analysis of the financial influx into CGT-related companies, including IPOs, SPACs, venture capital, and private funding.
- Strategic Deals: Insight into mergers & acquisitions, strategic investments, technology and research collaborations, and licensing agreements.
- Operational Transactions: Examination of manufacturing and supply chain deals, public outreach efforts, consumer education, philanthropy, and distribution partnerships.
- Market Dynamics: Breakdown of restructurings, joint ventures, terminations, and spinoffs impacting the CGT sector.
- Quarterly Analysis: Charts illustrating the frequency and types of deals throughout 2021, providing a clear view of market trends and activity changes per quarter.
Why This Report is Essential:
- Comprehensive Coverage: Tracks hundreds of cell and gene therapy deals, categorizing them into a usable format for easy reference.
- Market Insight: Offers in-depth analysis of key deals and strategic movements within the CGT industry.
- Investor Guidance: Provides valuable information for investors looking to understand the funding landscape and identify opportunities.
Additional Features:
- Vendor Profiles: Detailed profiles of leading companies involved in the CGT market.
- Visual Data Representation: Charts and graphs that visually represent deal activities and trends.
- Expert Analysis: Insights from Kalorama’s experienced analysts, offering expert perspectives on market developments.
Table: Total Quarterly Funding, By 2021 Quarter, By Type of Funding (in millions $) (%)
| Category | Q1 | Q2 | Q3 | Q4 | Total | % |
| M&A | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| VC/ Private | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| IPO/ FPO | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| SPAC | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Strat. Investment* | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Total | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
Chapter 1: Executive Summary
Introduction
$70 Billion in Funding During 2021
- Table 1-1: Total Quarterly Funding, By 2021 Quarter, By Type of Funding [/M&A; Venture Capital/Private; IPO/FPO; and SPAC] (note: also Strat. Inv. $600M min) ($M) (%)
- Figure 1-1: Total Quarterly Funding, By 2021 Quarter, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M)
Quarterly Funding in 2021
- Figure 1-2: Q1 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
- Figure 1-3: Q2 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
- Figure 1-4: Q3 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
- Figure 1-5: Q4 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
903 CGT Announcements from January 2021 through January 2022
- Table 1-2: Quarterly Count of Deals, By 2021 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
Uptick in Collaborations, Acquisitions, and Manufacturing/Supply Chain Deals Highlight Activity in Cell and Gene Therapy
- Figure 1-6: Most Frequent Types of Deals, by 2021 Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (total number)
A Look at Less Frequent CGT Deal Types
- Figure 1-7: Lower Frequency Deal Types, by 2021 Quarter, by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
- Table 1-3: Monthly Count of Deals [January 2021-January 2022], By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number, n=903) (%)
- Figure 1-8: Total Deals per Month, January 2021-January 2022 (total number)
- Figure 1-9: Most Frequent Types of Deals, by Month [January 2021-January 2022], by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (total number)
- Figure 1-10: Lower Frequency Deal Types, by Month [January 2021-January 2022], by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
- Figure 1-11: Acquisition Amount, by Quarter [January 2021-January 2022] ($M)
- Figure 1-12: Venture Capital/Private Funding Round Amount, by Quarter [January 2021-January 2022] ($M)
- Figure 1-13: IPO/FPO Amount, by Quarter [January 2021-December 2021] ($M)
- Figure 1-14: SPAC Amount, 2021 ($M)
Chapter 2: Venture Capital & Private Funding
VC/Private Funding in Flux
- Table 2-1: Quarterly Venture Capital/Private Total Funding, By Quarter [January 2021-January 2022], By Region [North America, Europe, APAC, Rest of World] ($M)
- Figure 2-1: Quarterly Venture Capital/Private Total Funding, By Quarter [January 2021-January 2022], By Region [North America, Europe, APAC, Rest of World] ($M)
- Figure 2-2: Venture Capital/Private Funding Round Amount, By Quarter [January 2021-January 2022], ($M)
- Table 2-2: Venture Capital/Private, January 2022
- Table 2-3: Venture Capital/Private, Q4 2021
- Table 2-4: Venture Capital/Private, Q3 2021
- Table 2-5: Venture Capital/Private, Q2 2021
- Table 2-6: Venture Capital/Private, Q1 2021
Chapter 3: Strategic Investments
Strategic Investments in Cell and Gene Therapy
- Table 3-1: Strategic Investments, January 2021-January 2022
Chapter 4: IPOs, FPOs, & SPACs
North America Sees Majority of Proceeds from IPOs, FPOs, and SPACs
- Table 4-1: Quarterly IPO/FPO Funding, By Region [North America, APAC, and Europe) ($M)
- Figure 4-1: Quarterly IPO/FPO Funding, By Region [North America, APAC, and Europe) ($M)
- Figure 4-2: IPO/FPO Amount, By Quarter [January 2021-January 2022] ($M)
- Table 4-2: Disclosed Quarterly SPAC Funding Portion ($M)
- Figure 4-3: Disclosed Q1-Q4 and January 2022 SPAC Funding Portion ($M)
- Table 4-3: IPO/FPO Deals, Q4 2021
- Table 4-4: IPO/FPO Deals, Q3 2021
- Table 4-5: IPO/FPO Deals, Q2 2021
- Table 4-6: IPO/FPO Deals, Q1 2021
- Table 4-7: SPAC Piece, January 2021-January 2022 ($M)
- Figure 4-4: SPAC Amount, 2021 ($M)
Chapter 5: Mergers & Acquisitions (M&A)
2021 Sees Spike in M&A Activity During Q3
- Table 5-1: Quarterly Merger and Acquisition Totals, January 2021-January 2022 ($M)
- Figure 5-1: Acquisition Amount, By Quarter [January 2021-January 2022], ($M)
- Table 5-2: Mergers and Acquisitions, January 2022 ($M)
- Table 5-3: Mergers and Acquisitions, Q4 2021 ($M)
- Table 5-4: Mergers and Acquisitions, Q3 2021 ($M)
- Table 5-5: Mergers and Acquisitions, Q2 2021 ($M)
- Table 5-6: Mergers and Acquisitions, Q1 2021 ($M)
Chapter 6: Technology/Research/Strategic Collaborations
CGT Market Sees an Assortment of Collaborations
- Table 6-1: Technology/Research/Strategic Collaboration Deals, January 2021-January 2022
Chapter 7: Licensing
A Look at Licensing in the Cell and Gene Therapy Market
- Table 7-1: Licensing Deals, January 2021-January 2022
Chapter 8: Manufacturing and Supply Chain
Examining Manufacturing and Supply Chain Management Activity in CGT
- Table 8-1: Manufacturing and Supply Chain Deals, January 2021-January 2022
Chapter 9: Public Outreach, Consumer Education, & Philanthropy
CGT Market Has Dozens of Announcements Related to Public Outreach, Patient/Consumer Education, and Philanthropy
- Table 9-1: Outreach, Education, & Philanthropy Deals, January 2021-January 2022
Chapter 10: Distribution & Co-Marketing
A Look at CGT Distribution and Co-Marketing Deals
- Table 10-1: Distribution & Co-Marketing Deals, January 2021-January 2022
Chapter 11: Other – Conclusion, Restructuring, JV, Termination, Spinoffs
A Look at Other Types of Deals Impacting Cell and Gene Therapy
- Table 11-1: Restructuring, JV, Termination, Spinoffs Deal, January 2021-January 2022
Related products
IVD Market Trends Report, March 2023
March 17, 2023
Diagnostic testing remains a cornerstone in healthcare, aiding physicians in diagnosis and providing crucial information for treatments like precision medicine. As we navigate the aftermath of the COVID-19 pandemic, the IVD market is evolving, driven by new products, shifts in global health spending, regulatory updates, and changing disease trends. Despite these shifts, the IVD market…
Price range: $3,000.00 through $4,500.00
In Vitro Diagnostic (IVD) Procedure Volumes, 2023-2028
October 22, 2023
Gain invaluable insights into the global IVD market with Kalorama Information’s comprehensive report In Vitro Diagnostic (IVD) Procedure Volumes (Chemistry, Immunoassays, Hematology, Microbiology, Histology, Point of Care), 2023-2028. This analysis provides essential data on the number of IVD procedures, offering a gold standard for new entrants and existing marketers in the diagnostic products industry.
…
Price range: $6,000.00 through $9,000.00
Clinical Laboratory Services Market, 8th Edition
May 18, 2023
Laboratories are the workhorse of diagnostic services for the IVD market. These laboratories play a vital role in providing analysis of a wide range of disorders and diseases including pathology, immunology, cholesterol testing, allergy testing, urinalysis, genetic testing and many more. Kalorama Information’s Clinical Laboratory Services Market, 8th Edition is your comprehensive resource for insights…
Price range: $4,000.00 through $6,000.00
